echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Qilu 2 heavy generic drugs approved: injection with albumin yew alcohol, tadalafi tablets!

    Qilu 2 heavy generic drugs approved: injection with albumin yew alcohol, tadalafi tablets!

    • Last Update: 2020-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Original: The White WordNovember 6, Qilu Pharmaceuticals two heavy-duty generic drugs were approved for the market, respectively, injection with yew alcohol (albumin binding type) and he Darafi tabletsSince all are registered in accordance with the 4 categories, approved as the same as through the consistency evaluation, so that these two heavyweight varieties in the domestic through the consistency evaluation of imitation enterprises have reached 3, injection with sequoia (albumin binding type)albumin yew alcohol developed by the United States Abraxis BioScience, is a new preparation combined with albumin, to overcome the common yew alcohol water solubility, low efficiency and side effects, etc, in January 2005 was approved by the FDA for treatment of breast cancer (commodity name Abraxe), and then approved for treatment of lung cancer, pancreatic cancerIn 2010, The new base acquired Abraxis for a down payment of $2.9 billion, pocketing Abraxane's revenueIn 2018, Abraxane's global sales will be approximately $1,062 millionAbraxane was approved in China in 2008/6/10In July 2017, Baiji Shenzhou acquired Abraxane's commercial rights in China through a deal with CelgeneQilu is the third domestic enterprise to obtain the listing qualification of the generic drug of this variety after Shi medicine and HengruiIn addition, Haizheng, Collum and Kangyu Biological and other enterprises of albumin yew alcohol listing application is also in the "review" stage
    from the median price of the winning bid, the new base, stone medicine and Hengrui, respectively, 5510, 2680 and 3280 yuan (100mg)It is worth noting that the new base has achieved a number of price reductions in Jiangsu, Shandong and other places of the latest winning bid price of 3350 yuan (100mg)source: PharmaGo winning database of the pharmaceutical rubula
    II, TadalafiTadalafi is a selective, reversible diesterase 5 (PDE5) inhibitor, the original manufacturer of Lilly The drug used to address the male erectile dysfunction (ED) indications and the West Dalafi, fadina non-difference is that the efficacy of tadallafi lasts up to 36 hours, much longer than the last two 3-4 hours of efficacy duration, reducing the patient's concerns about the length of time of the drug In addition, hedarafi has been approved for the treatment of benign prostate hyperplasia and pulmonary hypertension Lilly introduced a daily 5 mg dose of oral tadalafi on the basis of long-acting PDE5 inhibitors, revolutionizing a new model of male ED treatment that completely freed patients from taking the drug, and gradually lowered his market share of ED drugs and outplayed the much-known Viagra (West Nida) , Hedarafi Wason research was listed in China in November 2004, once a day 5mg small specifications are listed in China in December 2013, has now lost patent protection in China Qilu is the third domestic enterprise to obtain the listing of the generic drug after Changchun Haiyue and Nanjing Zhengda According to the PharmaGo database of the pharmaceutical rub, the variety has been approved for listing of the three manufacturers, including Hengrui, DongSunyan, including 13 enterprises in accordance with the new category 4 declaration In addition, five companies develop oral fluids and oral instant films.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.